The Cigna Group
—- Market cap
- $74.23B
- Debt
- —
- Cash
- −$7.68B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: CI stock price at discount vs WMT $280.91 current versus $905.16 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WMT's multiple
Implied fair value · at CI's multiple
Close Dec 31, 2025
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Lower P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 95% equity / 5% debt · EV / Revenue 1.29x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
WALMART INC. · implied price per share
Bear
$26.01
Base
$31.42
Bull
$38.87
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
CI vs UNH
CVS HEALTH Corp
CI vs CVS
HUMANA INC
CI vs HUM
CENTENE CORP
CI vs CNC
WEST PHARMACEUTICAL SERVICES INC
CI vs WST
BAXTER INTERNATIONAL INC
CI vs BAX
TARGET CORP
CI vs TGT
Costco Wholesale Corporation
CI vs COST
Amazon.com, Inc.
CI vs AMZN
Walgreens Boots Alliance, Inc.
CI vs WBA
DOLLAR GENERAL CORP
CI vs DG
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe CI can sustain double-digit revenue growth without further margin compression, then CI looks attractive to own or add because it trades at a steep discount to WMT on P/E, P/S, and EV/EBITDA despite acceptable quality metrics.
CI appears deeply discounted versus WMT on a relative basis: its P/E is 12.6x versus WMT at 40.8x, and its P/S and EV/EBITDA multiples are also far lower. The implied price of $905.16 versus the current price of $279.05 suggests a very large upside gap, but that result is driven by the P/E comparison and should be viewed cautiously given the different business models.
Supporting Metrics